EVEREST STUDY: Efficacy and Safety of Verteporfin Photodynamic Therapy in Combination with Ranibizumab or Alone Versus Ranibizumab Monotherapy in Patients with Symptomatic Macular Polypoidal Choroidal Vasculopathy
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Methods: In this multicenter, double-masked, primarily indocyanine green angiography–guided trial, 61 Asian patients were randomized to verteporfin PDT (standard fluence), ranibizumab 0.5 mg, or the combination. Patients were administered with verteporfin PDT/placebo and initiated with three consecutive monthly ranibizumab/sham injections starting Day 1, and re-treated (Months 3–5) as per predefined criteria. The primary endpoint was the proportion of patients with indocyanine green angiography–assessed complete regression of polyps at Month 6. Secondary endpoints included mean change in best-corrected visual acuity at Month 6 and safety. Results: At Month 6, verteporfin combined with ranibizumab or alone was superior to ranibizumab monotherapy in achieving complete polyp regression (77.8% and 71.4% vs. 28.6%; P < 0.01); mean change ± standard deviation in best-corrected visual acuity (letters) was 10.9 ± 10.9 (verteporfin PDT + ranibizumab), 7.5 ± 10.6 (verteporfin PDT), and 9.2 ± 12.4 (ranibizumab). There were no new safety findings with either drug used alone or in combination. Conclusion: Verteporfin PDT combined with ranibizumab 0.5 mg or alone was superior to ranibizumab monotherapy in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular polypoidal choroidal vasculopathy. All treatments were well tolerated over 6 months. EVEREST, the first, multicenter, double-masked, primarily indocyanine green angiography–guided randomized controlled trial for symptomatic macular polypoidal choroidal vasculopathy, demonstrated superiority of verteporfin photodynamic therapy combined with ranibizumab or alone over ranibizumab monotherapy in achieving complete regression of polyps at Month 6. Best-corrected visual acuity improved in all treatment arms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the United Kingdom, ICGA is not available in all units and is usually reserved for cases presenting with clinical features suspicious of polypoidal choroidopathy (IPCV) or retinal angiomatous proliferation (RAP) or when response to anti-VEGF therapy is suboptimal.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“Some lesion types are thought to be less responsive than others to anti-VEGF therapy, for example, IPCV.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“The EVEREST study suggested that combination therapy of IPCV with photodynamic therapy (PDT) and ranibizumab led to a better outcome than monotherapy with ranibizumab.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“However, an expanding or increased elevation in PED indicates activity that merits evaluation and treatment.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
Citations
Cites
Chung, S. E., Kang, S. W., Lee, J. H., & Kim, Y. T. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.012 · Cited by 580
Polypoidal Choroidal Vasculopathy: Incidence, Demographic Features, and Clinical Characteristics
Sho, K. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.10.1392 · Cited by 439 · cited 1×
“Moreover, the incidence of sub-RPE hemorrhage or subretinal hemorrhage in patients with PCV is high (30%–64%).(3,9) In a study of the natural history of patients with PCV, Uyama et al(6) reported that half of the study eyes had hemorrhagic episodes, recurrent leakage, or severe RPE atrophy after a long follow-up perio…”
BackgroundThe Expanding Clinical Spectrum of Idiopathic Polypoidal Choroidal Vasculopathy
Yannuzzi, L. A. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100150480005 · Cited by 436 · cited 3×
“It may be associated with a branching vascular network (BVN) and clinically visible orange-red subretinal nodule(s).(1) Polypoidal choroidal vasculopathy is prevalent in 10% to 54% of the Asian patients and in 8% to 12% of white patients with presumed exudative age-related macular degeneration (AMD).”
BackgroundPolypoidal choroidal vasculopathy: natural history
Uyama, M., Wada, M., Nagai, Y., Matsubara, T., Matsunaga, H., Fukushima, I., Takahashi, K., & Matsumura, M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01404-6 · Cited by 402 · cited 3×
“In PCV, the polypoidal lesions originate from the inner choroidal vasculature and can progress beneath the RPE.(1,6,7) The presence of orange-red nodule–like structures beneath the RPE associated with an adjacent serous pigment epithelial detachment or overlying neurosensory detachment, subretinal hemorrhage, and lipi…”
BackgroundTong, J.-P., Chan, W.-M., Liu, D. T. L., Lai, T. Y. Y., Choy, K.-W., Pang, C.-P., & Lam, D. S. C. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.10.012 · Cited by 385 · cited 1×
“The increased expression of VEGF in the aqueous humor of eyes with PCV provides a biologic rationale for treatment with anti-VEGF agents.(19) Limited data from case series with bevacizumab monotherapy have shown that treatment may reduce leakage associated with PCV but is ineffective for complete regression of the pol…”
BackgroundSelf-citationPhotodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy
Chan, W.-M., Lam, D. S. C., Lai, T. Y. Y., Liu, D. T. L., Li, K. K. W., Yao, Y., & Wong, T.-H. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.12.056 · Cited by 283
Self-citation(2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00223-x · Cited by 274 · cited 1×
“For CNV secondary to AMD, the Verteporfin In Photodynamic Therapy and the Treatment of AMD with Photodynamic Therapy study has demonstrated that there was gradual visual deterioration or no visual improvement with high re-treatment rate at 6 months for treated patients after verteporfin PDT administration.(25) This tr…”
ResultEfficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy
Gomi, F., Sawa, M., Sakaguchi, H., Tsujikawa, M., Oshima, Y., Kamei, M., & Tano, Y. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.122283 · Cited by 242 · cited 1×
“These findings are consistent with those reported earlier with other anti-VEGF therapies.(20,21)”
ResultGomi, F., Ohji, M., Sayanagi, K., Sawa, M., Sakaguchi, H., Oshima, Y., Ikuno, Y., & Tano, Y. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.02.031 · Cited by 239
The origins of polypoidal choroidal vasculopathy
Yuzawa, M. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.049296 · Cited by 198 · cited 4×
“Use of dynamic confocal scanning laser ophthalmoscope–ICGA may assist in further elucidating the BVN, from which these focal evaginating nodules arise, enabling clearer definition and differentiation from exudative AMD because of CNV.(7) Based on ICGA findings, PCV is defined as the presence of single or multiple foca…”
BackgroundInfluential
Cited by
Items 501–586 of 586
Broetto, B., Bermudes, F. H., Lavinsky, D., & Neto, L. B. (2024) · Springer eBooks · doi:10.1007/978-3-031-29358-0_8-1 · Cited by 1
Hata, M., Tsujikawa, A., & Yoshimura, N. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-3163-3
Author reply to comment on photodynamic therapy and polypoidal choroidal vasculopathy
Williams, G. S., Anderson, L., & Eddyshaw, D. (2014) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.146746
Toma, C., Lizzano, M., Giannì, L., Amisano, A., Periti, F., Imparato, M., Bianchi, A., & Vandelli, G. (2013) · Università degli Studi di Pavia · doi:10.6092/2039-1404.126.1519
“Analogamente lo studio multicent rico in doppio cieco EVEREST[8], eseguito su pazienti con vasculopatia polipoidale sintomatica con un fo llow-up di 6 mesi, mette in luce la superiorità dell a PDT con verteporfina combinata con Ranibizumab 0.”
BackgroundInfluentialAronés-Santivañez, J. R., Dyrda, A., & Valero, I. A. (2016) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2016.02.014
Imaging for branching vascular network in polypoidal choroidal vasculopathy
Vyas, C. H., Saurabh, K., & Roy, R. (2016) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.185616
Oishi, A., Oh, H., Mandai, M., Honda, S., & Miyamoto, N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.006
Extensive Serous Retinal Detachment after Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
Lee, T. H., Lee, S. J., & Nam, K. Y. (2016) · Journal of Retina · doi:10.21561/jor.2016.1.1.46
“실시키는 데 더 효과가 있음이 밝혀졌다[4].”
Aronés-Santivañez, J. R., Dyrda, A., & Valero, I. A. (2016) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2016.07.007
Alkın, Z. (2016) · Beyoglu Eye Journal · doi:10.14744/bej.43153
“Outcomes from the EVEREST study indicated that combining PDT with IVR resulted in fewer re-treatments with IVR over 5 months compared with IVR monotherapy (18).”
MethodGiant non-pulsatile polypoidal choroidal vasculopathy
Tay, E. L. T., & Laude, A. (2016) · International Journal of Ophthalmology · doi:10.18240/ijo.2016.12.26
Sonderformen choroidaler Neovaskularisationsmembranen
Sandner, D. (2017) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0042-123833
Anatomical and Functional Outcome: A Case of Idiopathic Polypoidal Choroidal Vasculopathy
Raman, P., & Ramli, N. M. (2017) · Anatomy & Physiology · doi:10.4172/2161-0940.1000266
Imaging and Diagnosis of Polypoidal Choroidal Vasculopathy
Wong, R. L. M., Ho, W.-L., Koizumi, H., & Wong, I. Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805313-3.00018-1
Han, J., Kim, S., & Oh, J. (2017) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2017.58.6.646
Perspectives in New Advances in Retinal Neovascularization Pathogenesis and Therapeutic Approaches
Sasore, T., & Ma, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-61115-0_19
Retinal Pigment Epithelial Detachment in Polypoidal Choroidal Vasculopathy
INHOFFEN, W. (2017) · Springer eBooks · doi:10.1007/978-3-319-56133-2_6
Ahmet, S. (2017) · Beyoglu Eye Journal · doi:10.14744/bej.2017.14633
“6% with ranibizumab monotherapy (6, 19) A mean of 5 injections were performed in the present study.”
Refractory Neovascular Age-related Macular Degeneration
Ma, D. J., & Yu, H. G. (2017) · Journal of Retina · doi:10.21561/jor.2017.2.2.51
“Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy (EVEREST) 연구에서는 라니비주맙으로 단독 치 료할 경우 광역학치료 단독 또는 광역학치료와 병합 치료할 경 우에 비하여 유의하게 결절의 완전 폐쇄율이 낮음이 보고되었 다[36].”
Ryu, G., Noh, D., Lee, J., & Sagong, M. (2017) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2017.58.12.1356
Polypoidal choroidal vasculopathy
Cheung, C. M. G., & Tan, G. S. W. (2014) · doi:10.2217/fmeb2013.13.244
Henaine-Berra, A., García‐Aguirre, G., Romo-Aguas, J. C., Santos-Palacios, A., Vélez-Montoya, R., & Fromow-Guerra, J. (2018) · Revista Mexicana de Oftalmología · doi:10.24875/rmo.m18000034
Solomon, S. D. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.07.001
Idiopathic Polypoidal Choroidal Vasculopathy – A Case Report
Gupta, R., Jahan, S., Nagpal, G., Akhtar, N., & Waris, A. (2016) · Madridge Journal of Ophthalmology · doi:10.18689/mjop-1000101
Srour, M., Sayag, D., Nghiem‐Buffet, S., Arndt, C., Creuzot-Garcher, C. P., Souied, E. H., & Mauget‐Faÿsse, M. (2019) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2019.05.002
Baskaran, P., Sindal, M. D., Dhoble, P., Ramakrishnan, S., Venkatesh, R., & Ramulu, P. Y. (2017) · GMS ophthalmology cases · doi:10.3205/oc000052 · Cited by 2
“This landmark trial has shown that both verteporfinmonotherapy and verteporfin and ranibizumab combination therapy are superior to ranibizumab monotherapy in achieving complete polyp regression [5].”
BackgroundPolypoidal Choroidal Vasculopathy: Diagnostic and Therapeutic Considerations
Koh, A. H. C. (2020) · Springer eBooks · doi:10.1007/978-981-15-2213-0_18
Self-citationGenomics in Choroidal Neovascularization
Yamashiro, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2213-0_6
Clinical Features of Eyes with Polypoidal Choroidal Vasculopathy and No Recurrence Over One Year
Park, J. H., Lee, K., & Park, Y. H. (2020) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2020.61.9.1048
Alex, D. (2021) · PARIPEX-INDIAN JOURNAL OF RESEARCH · doi:10.36106/paripex/0610647
Yoshida, I., Taniguchi, H., Sakamoto, M., & Maeno, T. (2021) · Clinical ophthalmology · doi:10.2147/opth.s305238
Manzur, F., Meza, V., Garretón, R., & Aldo Muñoz, Q. (2021) · Medwave · doi:10.5867/medwave.2021.08.8460
Thermal Laser Monotherapy for Extrafoveal Polypoidal Choroidal Vasculopathy
Radeck, V. M. M., Helbig, H., Valmaggia, C., & Barthelmes, D. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1608-1946
Chow, J. Y., She, P. F., Bastion, M.-L. C., & Muda, W. N. W. (2021) · Malaysian Journal of Ophthalmology · doi:10.35119/myjo.v3i3.136
陈, 青. (2021) · Hans Journal of Ophthalmology · doi:10.12677/hjo.2021.104026
Singh, S. R., Goud, N., Goud, A., Sahoo, N. K., Narayanan, R., & Chhablani, J. K. (2021) · Saudi Journal of Ophthalmology · doi:10.4103/1319-4534.337862
Eyes — the Window to your Soul (Vol. 21, No. 8, Full Issue)
(2017) · Asia-Pacific Biotech News · doi:10.1142/s0219030317001070
Polypoidal Choroidal Vasculopathy
Koh, A. (2014) · Springer eBooks · doi:10.1007/978-3-642-35951-4_982-1
Self-citation(2017) · Asia-Pacific Biotech News · doi:10.1142/s0219030317000556
Polypoidal Choroidal Vasculopathy
Koh, A. (2018) · Springer eBooks · doi:10.1007/978-3-540-69000-9_982 · Cited by 1
Self-citation(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00198-0
Iqbal, S., Manoj, S., Meel, N., & Nair, U. (2022) · Indian Journal of Clinical and Experimental Ophthalmology · doi:10.18231/j.ijceo.2022.105
Carta, V., Lixi, F., Tatti, F., & Peiretti, E. (2023) · Cureus · doi:10.7759/cureus.47942
Yuan, P. H., Khan, H. M., Sumita, F. A. G., Monteiro, M. L. R., Preti, R. C., & Navajas, E. V. (2023) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2023.10.006
Shah, S. V., Singh, S. R., Selvam, A., Harihar, S., Parmar, Y., Mangla, R., Arora, S., Vupparaboina, K. K., Venkatesh, R., & Chhablani, J. K. (2024) · International Journal of Retina and Vitreous · doi:10.1186/s40942-023-00512-6
“Both n-AMD and PCV are characterized by fibrovas-cular PED, and differences are related to PED height, notching, and the presence of polyps with or without branching vascular networks [10, 13].”
BackgroundPangal, E., & Özkırış, A. (2024) · Journal of Anatolian Medical Research · doi:10.55694/jamer.1385738 · Cited by 1
Zhang, Y., Cai, Q., Shan, S., She, X., Tao, J., Zhao, S., & Lv, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-3943737/v1
Ma, I.-H., Lai, T., Yang, C., Ho, T., Yang, C., & Hsieh, Y. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14060574
“In many clinical trials, the treatment goal for both nAMD and PCV was to achieve anatomical dryness without fluid in the intraretinal, subretinal, or sub-RPE layers [18,25–27].”
BackgroundSelf-citationSimultaneous Classification and Segmentation of Subretinal Lesions on ICGA Images
Kuan, M.-W., Lin, W.-Y., Tsai, C.-L., Chen, S., Ruamviboonsuk, P., & Jiang, D. (2024) · IEEE International Conference on Multimedia Information Processing and Retrieval (MIPR) · doi:10.1109/mipr62202.2024.00096
“We have conducted experiments using three datasets, namely the EVEREST dataset [5], the Taipei The rest of this paper is organized as follows.”
MethodSelf-citationTang, W., Qiu, X., Guo, J., Xu, G., Kong, L., & Liu, W. (2024) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-024-06681-w
“First, patients with PCV/AT1 often require multiple repeated injections of anti-VEGF drugs [5–7].”
Jafar, S. M., Hussein, Z. R., & Yasir, M. B. (2024) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2024.102225
Roisman, L., & Novais, E. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-29358-0_37-1
Cheung, C. M. G., Jackson, T. L., Wykoff, C. C., Khanani, A. M., Leitch, I. M., Baldwin, M. E., & Slakter, J. S. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100759 · Cited by 1
Ma, X., Han, D., Gao, J., Xu, Z., Qu, X., & Fu, Y. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03481-x
“Polyp regression was assessed via ICGA and classified into four categories: complete regression (no visible poly-poidal lesions), partial regression (≥ 10% reduction in polyp area), no change ( 10% reduction or increase in polyp area), and increased activity (≥ 10% increase in polyp area) [15].”
Roisman, L., & Novais, E. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-29358-0_37-2
Wang, T. H., Qu, J., Tang, R., Shi, X., Ying, X., Tao, Y., & Li, X. (2025) · Eye and Vision · doi:10.1186/s40662-025-00441-5
“Furthermore, compared with PDT, anti-VEGF therapy is associated with a lower risk of massive macular hemorrhage, retinal pigment epithelium (RPE) tear, and other complications [13].”
Japiassú, R. M., Cialdini, A. P., Hilgert, C. R., & Bach, B. (2025) · Springer eBooks · doi:10.1007/978-3-031-29358-0_90-1
Li, J., Xu, N., Jia, H., Wan, X., Wang, F., Zhou, M., Shen, M., Bo, Q., & Sun, X. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.8.12
“…ophthal-mologic examination, including fluorescein angiography (FA) and ICGA (Spectralis OCT + HRA; Heidelberg Engineering, Heidelberg, Germany), and the diagnosis of PCV was made based on the ICGA criteria used in the EVEREST study 17 by two senior retinal specialists (authors X.S. and F.W.).”
Khaohoen, A., & Chantarasorn, Y. (2025) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264251359847 · Cited by 1
“38 Although the difference is not significant, the prevalence of polypoidal lesions is greater in the pachychoroid neovasculopa-thy group (21/57) than in the drusen group (8/51).”
Yang, F., Luo, L., Li, Y., Wu, L., Wan, Q., Ji, W., & You, Z. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03642-y
“…that anti-VEGF treatment for IPCV over 6 months required an average of 5.2 injections, underscoring the need for effective treatment strategies [6]. t-PA combined with anti-VEGF treatment has shown promise in improving visual outcomes, but there are notable challenges, particularly the reduced…”
InfluentialLópez, S. A. M., & Medina, S. P. M. (2021) · Oftalmología clínica y experimental. · doi:10.70313/2718.7446.v14.n4.89
Xu, K., & Zhang, X. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03747-4
“Polyp regression was evaluated using ICGA and categorized into four groups: complete regression (no detectable polypoidal lesions), partial regression (a reduction of ≥ 10% in total polyp area), no change (< 10% change in polyp area), and increased activity (an increase of ≥ 10% in polyp area) [18].”
Gu, X., Zhao, Q., Wang, Y., Min, H., Zhao, X., & Chen, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-26031-y
“Diagnosis of PCV was established according to the EVEREST criteria 37 , while the other three conditions relied on a comprehensive evaluation of medical history and imaging modalities, such as color fundus photography (CFP), ultra-wide-field scanning laser ophthalmoscope (SLO), fundus fluorescein…”
The spectrum of pachychoroid neovasculopathy
Lingardo, S., Sacconi, R., Balduzzi, E., Beretta, F., Menean, M., & Querques, G. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-07031-0
Wang, Y., Chen, Z., Yu, W., & Chen, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16575326
Choi, J., Park, J. B., Lee, J., Kim, K., Kim, E. S., & Yu, S. (2025) · Eye · doi:10.1038/s41433-025-04190-6 · Cited by 2
“The inclusion criteria were as follows: treatment-naïve patients with PCV based on the EVEREST study criteria and using ICGA [11]; age ≥50 years; study eyes initially received three consecutive monthly intravitreal anti-VEGF injections; and patients who were followed up at least 3 years.”
Montrisuksirikun, C., Pongrujikorn, S., Rodanant, N., Thoongsuwan, S., Prakhunhungsit, S., Wongchaisuwat, N., & Phasukkijwatana, N. (2026) · International Journal of Retina and Vitreous · doi:10.1186/s40942-025-00795-x
“Patients diagnosed with PCV according to the EVEREST diagnostic criteria [1] who met the following inclusion criteria were enrolled in the study.”
Chaikitmongkol, V., Somkuna, T., Patikulsila, D., Ruamviboonsuk, P., Jirarattanasopa, P., Srisomboon, T., Narongchai, C., Ratanasukon, M., Bhurayanontachai, P., Kunavisarut, P., et al. (2026) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2026.100298
Self-citationCharles‐Messance, H. (2018) · theses.fr (ABES) · doi:10.70675/674377b7z4bf8z451cz9328zbe6648512747
Long-Term Management of Polypoidal Choroidal Vasculopathy: A Narrative Review
Koh, A., Staurenghi, G., Chhablani, J. K., Panos, G. D., Tan, C. S., Yamaguchi, T. C. N., & Empeslidis, T. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01365-6
“In the EVER-EST study, significantly more participants who received PDT plus ranibizumab achieved complete polyp regression at 6 months versus those who received ranibizumab alone ( p 0.01) [37].”
InfluentialSelf-citationChang, C., Liu, P., Cheng, K., Lai, H.-C., WU, H., Lee, D. Y., Lo, M.-W., Chen, K., Lin, H.-C., & Chang, Y. (2026) · International Ophthalmology · doi:10.1007/s10792-026-04061-3
Peripapillary Choroidal Neovascularization in Adults: Spectrum of Etiologies and Clinical Features
Vallino, V., Porreca, A., Bandello, F. M., Batlle-Ferrando, S., Bernal-Morales, C., Boscia, F., Breazzano, M. P., Bucceri, V., Chaundhary, V., Chhablani, J. K., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.5.29
Real-world durability challenges with nAMD treatments and the potential promise of gene therapy
Munk, M., Holz, F. G., Chow, D., Sala‐Puigdollers, A., Arias, L., Heier, J., Sakamoto, T., Souied, E. H., Godfrey, J., Douglas, K., et al. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2670008 · Cited by 1
“Even with many anti-VEGF options, there remains a population of refractive patients. nAMD patients of the polypoidal choroidal vasculopathy (PCV) subtype are known to exhibit a reduced or incomplete response to anti-VEGF 17 .”
Beyond the choroid: investigating scleral and iris thickness in the pachychoroid disease spectrum
Ulman, E. A., Degirmenci, C., Nalçacı, S., Afrashı, F., & Akkın, C. (2026) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-026-01378-5
“Patients meeting the diagnostic criteria for PCV, as defined in the EVEREST study [12], were classified as PCV cases.”
Chang, W., Kim, J., Jeon, J., & Park, S. (2026) · BMC Ophthalmology · doi:10.1186/s12886-026-05019-w
“Asian patients with nAMD exhibit distinct characteristics, including higher prevalence of polypoidal choroidal vasculopathy (PCV), accounting for 22–62% of cases [14, 15].”
Choi, J., Kim, D., Kim, K., & Yu, S. (2026) · Eye · doi:10.1038/s41433-026-04697-6
“The inclusion criteria were as follows: (1) treatment-naïve patients diagnosed with PCV according to the EVEREST study criteria [16] who were followed up for at least 3 years; (2) patients whose study eyes received three consecutive monthly intravitreal anti-VEGF injections, followed by a modified…”
Zhao, Q., Xie, Z., Zhao, X., Wei, L., Cheng, S., Gu, X., & Chen, Y. (2026) · Acta Ophthalmologica · doi:10.1111/aos.70190
“For CVD measurement obtained using 200°ultra-wide ICGA and FFA (Hirahara et al., 2016), differences in image acquisition timing may have been another contributing factor, with images captured 40 s to 2 min after dye injection in Lee, Ra, & Baek (2020) and 30–60 s after injection in Ra et al. (2024).”
InfluentialMark, H. N., & William, S. (2025) · Journal of Ophthalmic Science · doi:10.14302/issn.2470-0436.jos-25-5503
Kimura, M., Sakurada, Y., Fukuda, Y., Kotoda, Y., & Kashiwagi, K. (2026) · Pharmaceuticals · doi:10.3390/ph19091380
“Previous studies have demonstrated that combination therapy with photodynamic therapy (PDT) and anti-VEGF agents can achieve higher rates of early polyp regression compared with anti-VEGF monotherapy [6].”
Age-Related Hypofluorescent Indocyanine Green Angiography Spots
Cheung, C. M. G., Jiang, Z., Gilead, N., Kikushima, W., Curcio, C. A., & Chong, K. T. Y. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101400
Chaikitmongkol, V., Boonyot, P., Patikulsila, D., Pongsachareonnont, P., Jirarattanasopa, P., Sinawat, S., Surawatsatien, N., Ratanasukon, M., Choovuthayakorn, J., Kunavisarut, P., et al. (2026) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2026.3927
Japiassú, R. M., Cialdini, A. P., Hilgert, C. R., & Bach, B. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_90
Roisman, L., & Novais, E. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_37
Broetto, B., Bermudes, F. H., Lavinsky, D., & Neto, L. B. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_8
Chen, J.-W., Hwang, D., Hsieh, Y., Wu, W.-C., & Chen, S.-J. (2026) · Seminars in Ophthalmology · doi:10.1080/08820538.2026.2745913
Self-citationAi, L., Meng, X., He, S., Yuan, S., Zhang, Y., & Wang, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1981363
Metadata
- Authors
- Koh, A., Lee, W. K., Chen, L.-J., Chen, S.-J., Hashad, Y., Kim, H., Lai, T. Y., Pilz, S., Ruamviboonsuk, P., Tokaji, E., Weisberger, A., & Lim, T. H.
- Affiliations
- Eye & Retina Surgeons (SG)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Mackay Memorial Hospital (TW)
- Taipei Veterans General Hospital (TW)
- National Yang Ming University (TW)
- Corresponding author
- Koh, Adrian
- Hashad, Yehia
- Weisberger, Annemarie
- ORCID
- Venue
- Retina
- Published
- 2012-09
- Volume
- 32
- Issue
- 8
- Pages
- 1453-1464
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1976433015
- Cited by
- 587
- References
- 30
- Citations by year
- 2026: 21 · 2025: 39 · 2024: 32 · 2023: 20 · 2022: 31 · 2021: 54 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 63 · 2016: 52 · 2015: 51 · 2014: 39 · 2013: 41 · 2012: 8
- FWCI
- 41.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Retina (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Keywords
- verteporfin photodynamic therapy, ranibizumab, combination therapy, polyp regression, best-corrected visual acuity, anti-VEGF therapy, EVEREST trial
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Choroid, Combined Modality Therapy, Double-Blind Method, Coloring Agents, Female, Fluorescein Angiography, Humans, Indocyanine Green, Male, Middle Aged, Photochemotherapy, Polyps, Porphyrins, Visual Acuity, Choroid Diseases, Treatment Outcome, Photosensitizing Agents, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.